COMPANY PROFILE

Gemini Therapeutics

Explore full profile

Innovative therapies targeting genetically defined subpopulations in dry AMD and related diseases

Cambridge, United StatesFounded 2015Biotech & Life Sciences

Valuation $250–500M Last recorded · 2023

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Gemini Therapeutics

Gemini Therapeutics is a biotechnology company focused on developing precision medicines for genetically defined subpopulations affected by dry age-related macular degeneration (AMD) and related diseases. The company operates in the biopharmaceutical market, targeting common but poorly understood heterogeneous diseases. Gemini Therapeutics employs a therapeutic approach that leverages recombinant proteins, gene therapy, and monoclonal antibodies to create effective treatments. The business model revolves around identifying specific therapeutic candidates through scientific insights and conducting natural history studies to define target populations. Revenue is generated through the development and commercialization of these targeted therapies. The company serves patients suffering from dry AMD and related conditions, aiming to bring better medicine to millions of people worldwide.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Cambridge, United States
Employees: 1
Open positions: None listed
Dealroom signal: 26.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Investment activity: 1 company, latest Dec 2022
Capital deployed: —
Preferred round: SPAC IPO
Links: Website X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
IPO✓Exit	Feb 2021	$0	—	Undisclosed	—
SERIES A✓Equity / VC	Oct 2017	$43M	$170M	Atlas Venture · OrbiMed · Lightstone Ventures	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Gemini Therapeutics website traffic

Latest recorded traffic for Gemini Therapeutics is 210 monthly website visits, down 83.8% over the last three months. Gemini Therapeutics's team grew 0% over the past year.

Latest monthly visits210 3-month web change-83.8% 1-year team growth0%

Monthly website visitsOct 2017–Jun 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HTHarness TherapeuticsA private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs	Babraham, United Kingdom	Operational	5	$35M	$90M
KIKimialysDeveloper of an analytical device intended to offer products based on innovative surface chemistry in the field of biosensors	Paris, France	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
BPBrenus PharmaProducing the widest panel of tumor associated antigens and resistance markers with a chemical labeling enable to induce cell death by patients' immune system	Clermont-Ferrand, France	Operational
EBExeliom BiosciencesDeveloping single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics	Dijon, France	Operational
MTModalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders	Cambridge, United States	Operational
HPHcs PharmaA company specializing in cell imaging	Loos, France	Operational